Metformin use and the risk of colorectal adenoma: A systematic review and meta-analysis.

Jung, Yoon Suk; Park, Chan Hyuk; Eun, Chang Soo; Park, Dong Il; Han, Dong Soo
Journal of gastroenterology and hepatology
2017May ; 32 ( 5 ) :957-965.
저자 상세정보
Jung, Yoon Suk -
Park, Chan Hyuk -
Eun, Chang Soo -
Park, Dong Il -
Han, Dong Soo -
ABSTRACT
BACKGROUND AND AIM: Although it is known that metformin can reduce risk of colorectal cancer, it is unclear whether it protects against colorectal adenoma.

METHODS: This study conducted a systematic literature search on MEDLINE, EMBASE, and the Cochrane Library using the primary keywords "colorectal," "colon," "rectal," "rectum," "adenoma," "polyp," "neoplasia," "neoplasm," "metformin," and "diabetes." Studies were included if they evaluated the association between metformin use and colorectal adenoma and reported odds ratios (ORs) or provided data from which these could be estimated.

RESULTS: Ten studies and a total of 8726 patients were evaluated. Across all studies, a median of 32.1% (range: 15.2-53.0%) of patients taking metformin also had adenoma; a median of 43.5% (range: 20.5-59.6%) of those not taking metformin had adenoma. In our meta-analysis, metformin use reduced the risk of adenoma (pooled OR?=?0.76, 95% confidence interval [CI]?=?0.63-0.92, I(2) ?=?60%). Upon subgroup analyses, metformin use tended to reduce risk of adenoma in a high-risk population consisting of patients with a history of colorectal neoplasia (CRN) (pooled OR?=?0.61, 95% CI?=?0.34-1.10, I(2) ?=?79%). In addition, metformin reduced the risk of adenoma in a high-risk population consisting of patients with diabetes mellitus (pooled OR?=?0.75, 95% CI?=?0.62-0.91, I(2) ?=?57%). CONCLUSION: Metformin use seemed to be associated with a reduced risk of colorectal adenoma, especially in high-risk populations consisting of patients with diabetes mellitus or a history of CRN, although statistical power was not achieved in patients with a history of CRN. CI - ??2016 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Chemoprevention, colorectal adenoma, metformin
링크

주제코드
주제명(Target field)
연구대상(Population)
연구참여(Sample size)
대상성별(Gender)
질병특성(Condition Category)
연구환경(Setting)
연구설계(Study Design)
연구기간(Period)
중재방법(Intervention Type)
중재명칭(Intervention Name)
키워드(Keyword)
유효성결과(Recomendation)
Metformin use may reduce the risk of colorectal adenoma, especially in high risk populations including patients with DM.
연구비지원(Fund Source)
근거수준평가(Evidence Hierarchy)
출판년도(Year)
참여저자수(Authors)
대표저자
DOI
https://doi.org/10.1111/jgh.13639|
KCD코드
ICD 03
건강보험코드